Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6093806rdf:typepubmed:Citationlld:pubmed
pubmed-article:6093806lifeskim:mentionsumls-concept:C0015127lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0178719lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0026408lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0018284lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C1533157lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C0066318lld:lifeskim
pubmed-article:6093806lifeskim:mentionsumls-concept:C1292733lld:lifeskim
pubmed-article:6093806pubmed:issue2lld:pubmed
pubmed-article:6093806pubmed:dateCreated1984-12-10lld:pubmed
pubmed-article:6093806pubmed:abstractTextCultured fibroblasts were treated with the carboxylic ionophore monensin to study the effect on 125I-epidermal growth factor binding, internalization, and mitogenic response. Monensin enhanced the accumulation of the ligand by both preventing its degradation in lysosomes and causing a redistribution of receptors from the plasma membrane to an intracellular compartment. Monensin also prevented the mitogenic activity of EGF. This ionophore, like alkylamines, raises the pH of endosomes and lysosomes. These data are consistent with the hypothesis that exposure of EGF-receptor complexes to an acid environment is part of the pathway that leads to a mitogenic response.lld:pubmed
pubmed-article:6093806pubmed:languageenglld:pubmed
pubmed-article:6093806pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:citationSubsetIMlld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6093806pubmed:statusMEDLINElld:pubmed
pubmed-article:6093806pubmed:monthOctlld:pubmed
pubmed-article:6093806pubmed:issn0006-291Xlld:pubmed
pubmed-article:6093806pubmed:authorpubmed-author:KingA CAClld:pubmed
pubmed-article:6093806pubmed:issnTypePrintlld:pubmed
pubmed-article:6093806pubmed:day30lld:pubmed
pubmed-article:6093806pubmed:volume124lld:pubmed
pubmed-article:6093806pubmed:ownerNLMlld:pubmed
pubmed-article:6093806pubmed:authorsCompleteYlld:pubmed
pubmed-article:6093806pubmed:pagination585-91lld:pubmed
pubmed-article:6093806pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:meshHeadingpubmed-meshheading:6093806-...lld:pubmed
pubmed-article:6093806pubmed:year1984lld:pubmed
pubmed-article:6093806pubmed:articleTitleMonensin, like methylamine, prevents degradation of 125I-epidermal growth factor, causes intracellular accumulation of receptors and blocks the mitogenic response.lld:pubmed
pubmed-article:6093806pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6093806lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6093806lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6093806lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6093806lld:pubmed